Physician profile
Jennifer Smith
NPI 1952314767
$1,577.99
in general payments reported to CMS, 2019-2025
30 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.36 · 2020: $290 · 2021: $285 · 2022: $276 · 2023: $420 · 2024: $132 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.01 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $161.30 | 2019-2024 | |
| Lilly USA, LLC | $97.28 | 2021-2025 | Mounjaro |
| Amgen INC. | $95.08 | 2020-2024 | Otezla, Repatha |
| Ethicon US, LLC | $86.98 | 2020 | |
| Novo Nordisk INC | $77.18 | 2020-2023 | Ozempic, Rybelsus |
| Shield Therapeutics INC | $64.11 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $47.06 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $28.31 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $27.32 | 2019 | |
| Nestle Healthcare Nutrition INC. | $27.19 | 2020-2022 | |
| Allergan, INC. | $24.33 | 2020 | |
| Axsome Therapeutics, INC. | $23.48 | 2024 | Auvelity |
| Lundbeck LLC | $23.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.07 | 2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.68 | 2022 | |
| Nevro Corp. | $21.39 | 2023 | Senza |
| Exact Sciences Corporation | $19.36 | 2025 | The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $19.08 | 2025 | Voquezna |
| Biogen, INC. | $18.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $16.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2022 | |
| Amarin Pharma, INC. | $16.25 | 2019 | |
| Dexcom, INC. | $16.14 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.02 | 2023 | |
| Philips North America LLC | $13.02 | 2022 | |
| Corium, LLC | $12.99 | 2022 | |
| Genentech USA, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.